# Study Evaluating MST-997 in Advanced Malignant Solid Tumors

> **NCT00277836** · PHASE1 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 60 (—)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** MST-997

## Key facts

- **NCT ID:** NCT00277836
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 60 (—)
- **Last updated:** 2006-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00277836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00277836, "Study Evaluating MST-997 in Advanced Malignant Solid Tumors". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT00277836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*